Biotech · Private company
Castle Creek Pharmaceuticals, LLC
Track this companyFree. Adds Castle Creek Pharmaceuticals, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials70 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- diacerein 1% ointmentPhase 2 · Epidermolysis BullosaClinicalTrials.gov · fetched Nov 12, 2026
- diacerein 1% ointmentPhase 2 · Epidermolysis Bullosa SimplexClinicalTrials.gov · fetched Nov 12, 2026
- Diacerein 1% ointmentPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Diacerein 1% OintmentPhase 1 · Epidermolysis Bullosa (EB)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)PHASE1 · COMPLETED · started May 18, 2018ClinicalTrials.gov NCT03472287 · fetched Nov 12, 2026
- A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy SubjectsPHASE1 · COMPLETED · started Jan 15, 2018ClinicalTrials.gov NCT03472547 · fetched Nov 12, 2026
- A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% OintmentPHASE1 · COMPLETED · started Jan 9, 2018ClinicalTrials.gov NCT03472534 · fetched Nov 12, 2026
- A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy VolunteersPHASE1 · COMPLETED · started Jan 8, 2018ClinicalTrials.gov NCT03473197 · fetched Nov 12, 2026
- A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy VolunteersPHASE1 · COMPLETED · started Dec 12, 2017ClinicalTrials.gov NCT03473184 · fetched Nov 12, 2026
- Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa SimplexPHASE2 · COMPLETED · started Dec 1, 2017ClinicalTrials.gov NCT03389308 · fetched Nov 12, 2026
- Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)PHASE2 · TERMINATED · started Jun 1, 2017ClinicalTrials.gov NCT03154333 · fetched Nov 12, 2026